Search

The COVID-10 pandemic has slowed the pace of our lives in all aspects, temporarily halting screening and prophylaxis measures in every area, including health. Gastrointestinal (GI) cancers account for more than a quarter (26%) of the overall incidence of cancer and more than a third (35%) of all cancer deaths, which is why sustained efforts are needed to detect these neoplasms in situ, or even the discovery of the related precursors. Therefore, the resumption of screening programs and the recovery of the delayed period represent an extremely important and necessary objective. [ABSTRACT FROM AUTHOR]